Green light laser (KTP, 80 W) for the treatment of benign prostatic hyperplasia

Minerva Urologica e Nefrologica

Volumn 62, Issue 2, 2010, Pages 151-156

  Skriapas, K ^a   Hellwig, W ^a   Samarinas, M ^b   Witzsch, U ^a   Becht, E ^a  

^a Stiftung Zum Heiligen Geist ^*  (Germany)

^b UNIVERSITY GENERAL HOSPITAL OF PATRAS   (Greece)

Author keywords

Laser therapy; Prostate; Transurethral resection of prostate; Urinary bladder neck obstructionc

Indexed keywords

ACETYLSALICYLIC ACID; COUMARIN; LOW MOLECULAR WEIGHT HEPARIN; POTASSIUM DERIVATIVE; POTASSIUM TITANYL PHOSPHATE; TITANIUM DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLADDER NECK STENOSIS; CLINICAL EFFECTIVENESS; ECHOGRAPHY; HOSPITALIZATION; HUMAN; LASER SURGERY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; POSTOPERATIVE HEMORRHAGE; PROSTATE HYPERTROPHY; RESIDUAL URINE; RETROSPECTIVE STUDY; SAFETY; SCORING SYSTEM; TRANSURETHRAL ELECTROVAPORIZATION; URETHRAL CATHETERIZATION; URINE FLOW RATE; URINE RETENTION;

AGED; AGED, 80 AND OVER; HUMANS; LASERS, SOLID-STATE; MALE; MIDDLE AGED; PROSTATIC HYPERPLASIA; RETROSPECTIVE STUDIES;

EID: 77957700670     PISSN: 03932249     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984;132:474-9.
2. Garraway WM, Collins N, Lee RJ. High prevalence of benign prostatic hypertrophy in the community. Lancet 1991;338:469-71.
3. Madersbacher S, Alivizatos G, Nordling J, Sanz CR, Emberton M, de la Rosette JJ. EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptom suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol 2004;46:547-54.
4. Rassweiler J, Teber D, Kuntz R, Hofmann R. Complications of transurethral resection of the prostate (TURP)-incidence, management, and prevention. Eur Urol 2006;50:969-80.
5. Mebust WK, Holtgrewe HL, Cockett AT, Peters PC. Transurethral prostatectomy: immediate and postoperative complications. A cooperative study of 13 participating institutions evaluating 3.885 patients. J Urol 1989;141:243-7.
6. Te AE, Malloy TR, Stein BS, Ulchaker JC, Nseyo UO, Hai MA et al. Photoselective vaporization of the prostate for the treatment of benign prostatic hyperplasia: 12-results from the first United States multicenter prospective trial. J Urol 2004;172:1404-8.
7. Bachmann A, Reich O, Wyler S, Ruszat R, Casella R, Gasser T et al. The 80 W potassium-titanium-phosphate (KTP) laser vaporization of the prostate. Technique and follow-up after 70 procedures. Urologe A 2004;43:1262-70.
8. Bachmann A, Ruszat R, Wyler S, Reich O, Seifert HH, Müller A et al. Photoselective vaporization of the prostate: The Basel experience after 108 procedures. Eur Urol 2005;47:798-04.
9. Littlejohn Jr JO, Ghafar MA, Kang YM, Kaplan SA. Transurethral resection of the prostate: the new old standard. Curr Opin Urol 2002;12:19-23.
10. Madersbacher S, Marberger M. Is transurethral resection of the prostate still justified? BJU Int 1999;83:227-37.
11. Te AE. The development of laser prostatectomy. BJU Int 2004;93:262-5.
12. Reich O, Bachmann A, Siebels M, Hofstetter A, Stief CG, Sulser T. High power (80 W) potassium titanyl phosphate laser vaporization of the prostate in 66 high risk patients. J Urol 2005;173:158-60.
13. Sandhu JS, Ng CK, Gonzalez RR, Kaplan SA, Te AE. Photoselective laser vaporization prostatectomy in men receiving anticoagulants. J Endourol 2005;19:1196-8.
14. Ruszat R, Wyler S, Forster T, Reich O, Stief CG, Gasser TC et al. Safety and effectiveness of photoselective vaporization of the prostate (PVP) in patients on ongoing oral anticoagulation. Eur Urol 2007;51:1031-41.
15. Costello AJ, Bowsher WG, Bolton DM, Braslis KG, Burt J. Laser ablation of the prostate in patients with benign prostatic hypertrophy. Br J Urol 1992;69:603-8.
16. Kuntzman RS, Malek RS, Barrett DM, Bostwick DG. High-power (60-watt) potassium-titanyl-phosphate laser vaporization prostatectomy in living canines and in human and canine cadavers. Urology 1997;49:703-8.
17. Malek RS, Kuntzman RS, Barrett DM. High power potassium-titanyl-phosphate laser vaporization prostatectomy. J Urol 2000;163:1730-3.
18. Volkan T, Ihsan TA, Yilmaz O, Emin O, Selcuk S, Koray K,et al. Short term outcomes of high power (80 W) potassium-titanyl-phosphate laser vaporization of the prostate. Eur Urol 2005;48:608-13.
19. Heinrich E, Schiefelbein F, Schoen G. Technique and short-term outcome of green light laser (KTP, 80 W) vaporization of the prostate. Eur Urol 2007;52:1632-7.
20. Rajbabu K, Chandrasekara SK, Barber NJ, Walsh K, Muir GH et al. Photoselective vaporization of the prostate with the potassium-titalyl-phosphate laser in men with prostates of >100 mL. BJU Int 2007;100:593-8.
21. Malek RS, Kuntzman RS, Barrett DM. photoselective potassium-titalyl- phosphate laser vaporization of the benign obstructive prostate: observations on long-term outcomes. J Urol 2005;174:1344-8.
22. Sandhu JS, Ng C, Vanderbrink BA, Egan C, Kaplan SA, Te AE. High-power potassium-titalyl-phosphate photoselective laser vaporization of prostate for treatment of benign prostate hyperplasia in men with large prostates. Urology 2004;64:1155-9.
23. Te AE, Malloy TR, Stein BS, Ulchaker JC, Nseyo UO, Hai MA. Impact of prostate-specific antigen level and prostate volume as predictors of efficacy in photoselective vaporization prostatectomy: analysis and results of an ongoing prospective multicentre study at 3 years. BJU Int 2006;97:1229-33.
24. Kumar SM. Photoselective vaporization of the prostate: a volume redaction analysis in patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia and carcinoma of the prostate. J Urol 2005;173:511-3.